Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug [Seeking Alpha]
Athira Pharma, Inc. (ATHA)
Company Research
Source: Seeking Alpha
Gti861/iStock via Getty ImagesIt Will Take an Arsenal of Treatments to Fight Alzheimerâ??sThere is more reason for optimism now than ever before.H. Fillit, MD, Co-founder and CSO of the Alzheimer's Drug Discovery Foundation,Wall Street Journal, June, 9, 2022ThesisAfter the severe drop on not meeting its primary endpoint for the entire study population, Athira Pharma (NASDAQ:ATHAI believe thedataWith the company already trading at cash level before the readout, and the subsequent huge drop, I find myself actually being much more excited than the market.Solving Alzheimer's disease may require more approach than one, and targeting the HGF/MET pathway could well be one, albeit in a subgroup.Athira Pharma, its pipeline and expected readoutAthira Pharma ("ATHA"Athira pipeline(Company website)This article will focus on its Alzheimerâ??s programs with ATH-1017 or fosgonimeton, which the company itself focuses on primarily and which has two trials ongoing, entitled ACT-AD for the Phase 2 trial
Show less
Read more
Impact Snapshot
Event Time:
ATHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHA alerts
High impacting Athira Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATHA
News
- One Athira Pharma Insider Raised Their Stake In The Previous Year [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerGlobeNewswire
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseGlobeNewswire
ATHA
Earnings
- 11/9/23 - In-Line
ATHA
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 3
- 4/9/24 - Form ARS
- ATHA's page on the SEC website